What it does
Weight LossBlood Sugar ControlMetabolic SyndromeInsulin ResistanceAppetite Suppression
Tirzepatide was the first GIP/GLP-1 dual agonist approved for clinical use. The GIP component adds a second satiety pathway on top of GLP-1 signaling, producing stronger appetite suppression and better tolerability than GLP-1 alone. Clinical trial data is the strongest of any GLP-1 class peptide available. Most members tolerate it well, with GI side effects concentrated in the first 4-6 weeks of each escalation step.
Reconstitution
Mixing Instructions
1
Add 3mL bacteriostatic water to your 30mg vial.
2
Inject slowly along the glass wall. Do not aim at the powder.
3
Gently swirl until clear. Do not shake.
4
Label with date. Refrigerate. For best results, use within 28 days of reconstitution.
Dosing Reference
Based on standard reconstitution above. All doses subcutaneous unless noted.
Based on 3mL reconstitution · 10mg/mL · Once weekly subcutaneous.
| Dose | Syringe (units) | Volume (mL) |
|---|---|---|
| 2.5mg — starter | 25 units | 0.25mL |
| 5.0mg | 50 units | 0.50mL |
| 7.5mg | 75 units | 0.75mL |
| 10.0mg | 100 units | 1.0mL |
Protocol
Research Protocol
Weeks 1-42.5mg per week (1.25mg x2, Mon/Thu)
Weeks 5-85mg per week (2.5mg x2, Mon/Thu)
Weeks 9-127.5mg per week (3.75mg x2, Mon/Thu)
Weeks 13+10-15mg per week based on tolerance
RouteSubcutaneous
Cycle12-48 weeks
Split doseRecommended - divide weekly dose Mon/Thu
All BodhiPep compounds are for research use only. For educational purposes only.